Eli Lilly and AstraZeneca Drop PhIII Alzheimer's Candidate – BACE Class May Be Done

Eli Lilly (NYSE: LLY) and AstraZeneca are discontinuing the global Phase 3 clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease.